{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:24:33Z","timestamp":1787037873555,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-02857-9","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:39:53Z","timestamp":1774931993000},"page":"1997-2008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient characteristics and prognostic factors in advanced treatment lines in metastatic neuroendocrine tumors"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-0206","authenticated-orcid":false,"given":"Philipp","family":"Melhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genti","family":"Zhitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-2371","authenticated-orcid":false,"given":"Barbara","family":"Kiesewetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"10","key":"2857_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y et al (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 3(10):1335\u20131342","journal-title":"JAMA Oncol"},{"issue":"1","key":"2857_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA et al (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33(1):115\u2013154","journal-title":"Endocr Pathol"},{"issue":"2","key":"2857_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/endrev\/bnz004","volume":"41","author":"J Hofland","year":"2020","unstructured":"Hofland J, Kaltsas G, de Herder WW (2020) Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev 41(2):371\u2013403","journal-title":"Endocr Rev"},{"key":"2857_CR4","doi-asserted-by":"crossref","unstructured":"Loree JM, Chan D, Lim J, Stuart H, Fidelman N, Koea J et al (2024) Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs. JAMA Oncol 10(12):1707\u20131720","DOI":"10.1001\/jamaoncol.2024.4330"},{"issue":"5","key":"2857_CR5","doi-asserted-by":"publisher","first-page":"101794","DOI":"10.1016\/j.beem.2023.101794","volume":"37","author":"N Fazio","year":"2023","unstructured":"Fazio N, La Salvia A (2023) Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023? Best Pract Res Clin Endocrinol Metab 37(5):101794","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"2857_CR6","doi-asserted-by":"publisher","first-page":"e2124750","DOI":"10.1001\/jamanetworkopen.2021.24750","volume":"4","author":"Z Xu","year":"2021","unstructured":"Xu Z, Wang L, Dai S, Chen M, Li F, Sun J et al (2021) Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open 4(9):e2124750","journal-title":"JAMA Netw Open"},{"key":"2857_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ejca.2022.06.003","volume":"172","author":"IN Pole\u00e9","year":"2022","unstructured":"Pole\u00e9 IN, Hermans BCM, van der Zwan JM, Bouwense SAW, Dercksen MW, Eskens F et al (2022) Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study. Eur J Cancer 172:252\u2013263","journal-title":"Eur J Cancer"},{"issue":"9","key":"2857_CR8","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/annonc\/mdq022","volume":"21","author":"R Garcia-Carbonero","year":"2010","unstructured":"Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, D\u00edaz-P\u00e9rez JA, Del Mart\u00ednez MP, Alonso Ordu\u00f1a V et al (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794\u20131803","journal-title":"Ann Oncol"},{"issue":"6","key":"2857_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jtho.2019.02.002","volume":"14","author":"P Robelin","year":"2019","unstructured":"Robelin P, Hadoux J, Forestier J, Planchard D, Hervieu V, Berdelou A et al (2019) Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. J Thorac Oncol 14(6):993\u20131002","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2857_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1634\/theoncologist.2017-0364","volume":"23","author":"B Nu\u00f1ez-Valdovinos","year":"2018","unstructured":"Nu\u00f1ez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Casta\u00f1o-Pascual \u00c1, Benavent M et al (2018) Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist 23(4):422\u2013432","journal-title":"Oncologist"},{"issue":"4","key":"2857_CR11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/cncr.24065","volume":"115","author":"JS Hill","year":"2009","unstructured":"Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF et al (2009) Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 115(4):741\u2013751","journal-title":"Cancer"},{"issue":"12","key":"2857_CR12","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2967\/jnumed.115.162719","volume":"56","author":"V Ambrosini","year":"2015","unstructured":"Ambrosini V, Campana D, Polverari G, Peterle C, Diodato S, Ricci C et al (2015) Prognostic Value of 68Ga-DOTANOC PET\/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas. J Nucl Med 56(12):1843\u20131848","journal-title":"J Nucl Med"},{"issue":"4","key":"2857_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S et al (2017) Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 18(4):525\u2013534","journal-title":"Lancet Oncol"},{"issue":"7","key":"2857_CR14","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.cgh.2008.02.052","volume":"6","author":"R Arnold","year":"2008","unstructured":"Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ et al (2008) Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 6(7):820\u2013827","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2857_CR15","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1210\/jc.2011-0666","volume":"96","author":"JC Yao","year":"2011","unstructured":"Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J et al (2011) Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96(12):3741\u20133749","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2857_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10620-006-9345-4","volume":"51","author":"TE Clancy","year":"2006","unstructured":"Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH (2006) Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51(5):877\u2013884","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2857_CR17","doi-asserted-by":"publisher","first-page":"e13381","DOI":"10.1111\/jne.13381","volume":"36","author":"LJ Cui","year":"2024","unstructured":"Cui LJ, Yu FH, Cheng ZX, Su F, Chen YY, Tan HY (2024) Prognostic value of inflammation-related biomarkers in patients with gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. J Neuroendocrinol 36(4):e13381","journal-title":"J Neuroendocrinol"},{"key":"2857_CR18","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.3390\/cancers14215465","volume":"14(21)","author":"N Gebauer","year":"2022","unstructured":"Gebauer N, Ziehm M, Gebauer J, Riecke A, Meyh\u00f6fer S, Kulemann B et al (2022) The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic (GEP-NEN) System. Cancers (Basel) 14(21):5465","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2857_CR19","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s40618-024-02346-x","volume":"47","author":"A La Salvia","year":"2024","unstructured":"La Salvia A, Marcozzi B, Manai C, Mazzilli R, Landi L, Pallocca M et al (2024) Rachel score: a nomogram model for predicting the prognosis of lung neuroendocrine tumors. J Endocrinol Invest 47(10):2575\u20132586","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2857_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1530\/ERC-17-0489","volume":"25","author":"S Pusceddu","year":"2018","unstructured":"Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R et al (2018) A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocr Relat Cancer 25(6):607\u2013618","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2857_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","volume":"128","author":"DL Chan","year":"2023","unstructured":"Chan DL, Hayes AR, Karfis I, Conner A, Furtado O\u2019Mahony L, Mileva M et al (2023) Dual [(68)Ga]DOTATATE and [(18)F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer 128(4):549\u2013555","journal-title":"Br J Cancer"},{"issue":"4","key":"2857_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1634\/theoncologist.2016-0351","volume":"22","author":"F Panzuto","year":"2017","unstructured":"Panzuto F, Merola E, Pavel ME, Rinke A, Kump P, Partelli S et al (2017) Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist 22(4):409\u2013415","journal-title":"Oncologist"},{"issue":"32","key":"2857_CR23","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","volume":"34","author":"JC Yao","year":"2016","unstructured":"Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U et al (2016) Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol 34(32):3906\u20133913","journal-title":"J Clin Oncol"},{"issue":"12","key":"2857_CR24","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A et al (2021) (177)Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752\u20131763","journal-title":"Lancet Oncol"},{"issue":"1","key":"2857_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000443612","volume":"104","author":"A Rinke","year":"2017","unstructured":"Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM et al (2017) Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology 104(1):26\u201332","journal-title":"Neuroendocrinology"},{"issue":"14","key":"2857_CR26","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/cncr.30057","volume":"122","author":"Q Qi","year":"2016","unstructured":"Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H et al (2016) A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer 122(14):2158\u20132167","journal-title":"Cancer"},{"issue":"43","key":"2857_CR27","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan LDA, Fran\u00e7ois R et al (2019) Welcome to the Tidyverse. J Open Source Softw 4(43):1686","journal-title":"J Open Source Softw"},{"issue":"1","key":"2857_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","volume":"13","author":"DD Sjoberg","year":"2021","unstructured":"Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J (2021) Reproducible summary tables with the gtsummary package. R J 13(1):570\u2013580","journal-title":"R J"},{"key":"2857_CR29","doi-asserted-by":"publisher","unstructured":"Iannone R, Cheng J, Schloerke B, Hughes E, Lauer A, Seo J (2024) gt: Easily Create Presentation-Ready Display Tables. R package version 0.11.1 [Available from: https:\/\/doi.org\/10.32614\/CRAN.package.gt ]","DOI":"10.32614\/CRAN.package.gt"},{"key":"2857_CR30","doi-asserted-by":"publisher","unstructured":"Wilke C (2024) cowplot Streamlined Plot Theme and Plot Annotations for \u2018ggplot2\u2019. R package version 1.1.3 [Available from: https:\/\/doi.org\/10.32614\/CRAN.package.cowplot ]","DOI":"10.32614\/CRAN.package.cowplot"},{"key":"2857_CR31","doi-asserted-by":"publisher","unstructured":"Rudis B, Gandy D (2023) waffle: Create Waffle Chart Visualizations. R package version 1.0.2 [Available from: https:\/\/doi.org\/10.32614\/CRAN.package.waffle ]","DOI":"10.32614\/CRAN.package.waffle"},{"key":"2857_CR32","doi-asserted-by":"publisher","unstructured":"Jeppson H, Hofmann H, Cook D (2021) ggmosaic: Mosaic Plots in the \u2018ggplot2\u2019 Framework. R package version 0.3.3 [Available from: https:\/\/doi.org\/10.32614\/CRAN.package.ggmosaic ]","DOI":"10.32614\/CRAN.package.ggmosaic"},{"key":"2857_CR33","doi-asserted-by":"publisher","unstructured":"Gordon M, Lumley T (2024) forestplot: Advanced Forest Plot Using \u2018grid\u2019 Graphics. R package version 3.1.6 [Available from: https:\/\/doi.org\/10.32614\/CRAN.package.forestplot ]","DOI":"10.32614\/CRAN.package.forestplot"},{"key":"2857_CR34","doi-asserted-by":"publisher","unstructured":"Sjoberg D, Baillie M, Fruechtenicht C, Haesendonckx S, Treis T (2025) ggsurvfit: Flexible Time-to-Event Figures. R package version 1.2.0 [Available from: https:\/\/doi.org\/10.32614\/CRAN.package.ggsurvfit ]","DOI":"10.32614\/CRAN.package.ggsurvfit"},{"key":"2857_CR35","doi-asserted-by":"publisher","unstructured":"Therneau T (2024) A Package for Survival Analysis in R. R package version 3.8-3 [Available from: https:\/\/doi.org\/10.32614\/CRAN.package.survival ]","DOI":"10.32614\/CRAN.package.survival"},{"issue":"1","key":"2857_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00259-025-07411-y","volume":"53","author":"P Melhorn","year":"2025","unstructured":"Melhorn P, Kretschmer-Chott E, Mazal P, Raderer M, Kiesewetter B (2025) Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios. Eur J Nucl Med Mol Imaging 53(1):263\u2013274","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"18","key":"2857_CR37","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al (2008) One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063\u20133072","journal-title":"J Clin Oncol"},{"issue":"2","key":"2857_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1530\/ERC-12-0340","volume":"20","author":"M Ter-Minassian","year":"2013","unstructured":"Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R et al (2013) Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer 20(2):187\u2013196","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2857_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al (2017) Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376(2):125\u2013135","journal-title":"N Engl J Med"},{"key":"2857_CR40","doi-asserted-by":"crossref","unstructured":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S et al (2025) Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med 392(7):653\u2013665","DOI":"10.1056\/NEJMoa2403991"},{"key":"2857_CR41","doi-asserted-by":"publisher","first-page":"672499","DOI":"10.3389\/fendo.2021.672499","volume":"12","author":"E Giannetta","year":"2021","unstructured":"Giannetta E, La Salvia A, Rizza L, Muscogiuri G, Campione S, Pozza C et al (2021) Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms? Front Endocrinol (Lausanne) 12:672499","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2857_CR42","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12020-021-02942-4","volume":"76","author":"G Puliani","year":"2022","unstructured":"Puliani G, Sesti F, Anastasi E, Verrico M, Tarsitano MG, Feola T et al (2022) Angiogenic factors as prognostic markers in neuroendocrine neoplasms. Endocrine 76(1):208\u2013217","journal-title":"Endocrine"},{"issue":"3","key":"2857_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/CAD.0000000000000909","volume":"31","author":"T Grenader","year":"2020","unstructured":"Grenader T, Pavel ME, Ruszniewski PB, \u0106wik\u0142a JB, Phan AT, Raderer M et al (2020) Prognostic value of the neutrophil\/lymphocyte ratio in enteropancreatic neuroendocrine tumors. Anticancer Drugs 31(3):216\u2013222","journal-title":"Anticancer Drugs"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02857-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02857-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02857-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:30:05Z","timestamp":1787034605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02857-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2857"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02857-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest related to the present work. BK received honoraria for lectures or advisory board participation from the following for-profit companies (all outside of the submitted work): from AAA, AstraZeneca, BMS, Boehringer Ingelheim, Ipsen, MSD, Novartis, Eli Lilly, Roche, and Janssen Cilag. MR received honoraria for lectures or advisory board participation from the following for-profit companies (all outside of the submitted work): AbbVie, Gilead, Galapagos Pharma, Celgene, BMS, Ipsen, Novartis, Roche, Eisai, and Eli Lilly. All other authors have no disclosures to report.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has received approval from the Ethics Committee of the Medical University of Vienna (EK No: 1852\/2023).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial intelligence (AI)-based technologies were used in the conduct of this study. ChatGPT version 4 and newer (OpenAI, Inc.; 2023-2026; https:\/\/chatgpt.com\/) was used to support R programming for statistical analyses and data visualization. The author(s) reviewed all outputs of this AI-assisted tool\/service and edited the content as needed and take(s) full responsibility for the accuracy and integrity of this work.","order":3,"name":"Ethics","label":"Statement on the use of artificial intelligence","group":{"name":"EthicsHeading","label":"Declarations"}}]}}